NEW YORK (GenomeWeb) — WuXi NextCode said today that it has closed a $200 million Series C financing round. The round was led by the Ireland Strategic Investment Fund (ISIF), which contributed $70 million, and included existing shareholders Temasek, Yunfeng Capital, and Sequoia Capital.
Shanghai-based genomic information company WuXi NextCode has raised $200m in a series C funding round led by the Ireland Strategic Investment Fund. The latest cash injection will allow the firm to grow its newly acquired business in Dublin, Genomics Medicine Ireland, which was bought as part of a $400m investment in Irish precision medicine. The focus will be placed on the company's disease biomarker identification initiative, as well as its population genomics study, which will sequence the genomes of 400,000 Irish citizens. In an interview with Bloomberg, CEO and co-founder Dr David O’Connor said that his team had been working for several years now on developing next-generation sequencing technology at WuXi.